Skip to main content

CORRECTION article

Front. Immunol., 21 November 2022
Sec. Cancer Immunity and Immunotherapy
Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.1078003
This article is part of the Research Topic Insights in Cancer Immunity and Immunotherapy: 2022 View all 16 articles

Corrigendum: Ligand-based CAR T-cell: Different strategies to drive T-cells in future new treatments

This article is a correction to:

  1. Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments

    1. Read original article
Alejandro Ramírez-Chacn,Alejandro Ramírez-Chacón1,2Sergi Betriu-Mndez,Sergi Betriu-Méndez3,4Ariadna Bartol-Ibars,Ariadna Bartoló-Ibars3,4Azucena Gonzlez,,Azucena González3,4,5Merc Martí,Mercè Martí1,2Manel Juan,,*Manel Juan3,4,5*
  • 1Immunology Unit, Department of Cellular Biology, Physiology and Immunology, Universitat Autònoma de Barcelona (UAB), Cerdanyola del Vallès, Spain
  • 2Laboratory of Cellular Immunology, Institute of Biotechnology and Biomedicine (IBB), Cerdanyola del Vallès, Spain
  • 3Immunology Department, Hospital Cl´ınic de Barcelona, Centre de Diagnòstic Biomèdic (CDB), Barcelona, Spain
  • 4Immunology Department, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) –Fundació Clínic per a la Recerca Biomèdica (FCRB) Universitat de Barcelona (UB), Barcelona, Spain
  • 5Immunology Department, Hospital Sant Joan de Déu, Barcelona, Spain

A corrigendum on
Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments

by Ramírez-Chacón A, Betriu-Méndez S, Bartoló-Ibars A, González A, Martí M and Juan M (2022) Front. Immunol. 13:932559. doi: 10.3389/fimmu.2022.932559

In the published article, there was an error in the Funding statement. Missing grant supporting this manuscript. The correct Funding statement appears below.

Funding

“Thanks to Immunology department (Hospital Clínic de Barcelona) and Institute of Biotechnology and Biomedicine (IBB-UAB) for their help during the writing of this article. This work has been partially supported by grants from the Instituto de Salud Carlos III, Spanish Ministry of Health (FIS PI18/00775, PICI18/00012 and complementary grant for CONCORD-023), Fondo Europeo de Desarrollo Regional (FEDER) “una manera de hacer Europa”, “La Caixa” Foundation (CP042702/LCF/PR/GN18/50310007), and Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement, Generalitat de Catalunya, project 2020PANDE00079.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: T cells, chimeric antigen receptor (CAR), ligands, receptor, antigen, CAAR, BAR

Citation: Ramírez-Chacón A, Betriu-Méndez S, Bartoló-Ibars A, González A, Martí M and Juan M (2022) Corrigendum: Ligand-based CAR T-cell: Different strategies to drive T-cells in future new treatments. Front. Immunol. 13:1078003. doi: 10.3389/fimmu.2022.1078003

Received: 23 October 2022; Accepted: 09 November 2022;
Published: 21 November 2022.

Edited and Reviewed by:

Catherine Sautes-Fridman, INSERM U1138 Centre de Recherche des Cordeliers (CRC), France

Copyright © 2022 Ramírez-Chacón, Betriu-Méndez, Bartoló-Ibars, González, Martí and Juan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Manel Juan, bWp1YW5AY2xpbmljLmNhdA==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.